| Title |
Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee
|
|---|---|
| Published in |
Arthritis Research & Therapy, October 2012
|
| DOI | 10.1186/ar4044 |
| Pubmed ID | |
| Authors |
Walter P Maksymowych, Anthony S Russell, Peter Chiu, Alex Yan, Niall Jones, Tracey Clare, Robert GW Lambert |
| Abstract |
ABSTRACT: INTRODUCTION: Inflammation associated with synovial expression of TNFα is a recognised feature of osteoarthritis (OA), although no studies have yet reported beneficial effects of anti-TNFα therapy on clinical manifestations of inflammation in OA. METHODS: We conducted an open-label evaluation of adalimumab over 12 weeks in 20 patients with OA of the knee and evidence of effusion clinically. Inclusion criteria included daily knee pain for the month preceding study enrolment and a summed pain score of 125 to 400 mm visual analogue scale on the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain subscale. The primary outcome was the Osteoarthritis Research Society International/Outcome Measures in Rheumatology Clinical Trials (OARSI/OMERACT) response criterion at week 12. Secondary outcomes included the WOMAC pain score 20% and 50% improvement, WOMAC stiffness and function scores, patient and physician global visual analogue scale, as well as target joint swelling. RESULTS: Treatment was well tolerated and completed by 17 patients with withdrawals unrelated to lack of efficacy or adverse events. By intention to treat, an OARSI/OMERACT response was recorded in 14 (70%) patients. WOMAC pain 20% and 50% responses were recorded in 14 (70%) patients and eight (40%) patients, respectively. Significant improvement was observed in mean WOMAC pain, stiffness, function, physician and patient global, as well as target joint swelling at 12 weeks (P < 0.0001 for all). After treatment discontinuation, 16 patients were available for assessment at 22 weeks and OARSI/OMERACT response compared with baseline was still evident in 10 (50%) patients. CONCLUSION: Targeting TNFα may be of therapeutic benefit in OA and requires further evaluation in controlled trials. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00686439. |
Mendeley readers
The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 1% |
| Germany | 1 | 1% |
| United Kingdom | 1 | 1% |
| Denmark | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 95 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 13% |
| Researcher | 11 | 11% |
| Student > Master | 10 | 10% |
| Student > Postgraduate | 8 | 8% |
| Other | 8 | 8% |
| Other | 21 | 21% |
| Unknown | 29 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 32% |
| Agricultural and Biological Sciences | 7 | 7% |
| Nursing and Health Professions | 5 | 5% |
| Immunology and Microbiology | 3 | 3% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 13 | 13% |
| Unknown | 37 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2022.
All research outputs
#5,422,967
of 25,374,647 outputs
Outputs from Arthritis Research & Therapy
#1,250
of 3,381 outputs
Outputs of similar age
#39,385
of 191,555 outputs
Outputs of similar age from Arthritis Research & Therapy
#9
of 43 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,381 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 191,555 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.